Development of pulmonary arterial hypertension in women: Interplay of sex hormones and pulmonary vascular disease

Women's Health

Volumn 6, Issue 2, 2010, Pages 285-296

  Pugh, Meredith E ^a   Hemnes, Anna R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gender; Pulmonary arterial hypertension; Pulmonary hypertension; Sex; Vascular response

Indexed keywords

AMBRISENTAN; BOSENTAN; ESTROGEN; ILOPROST; PRASTERONE; PROSTACYCLIN; SEX HORMONE; SILDENAFIL; SITAXSENTAN; TADALAFIL; TESTOSTERONE; UNIPROST;

DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG HALF LIFE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HORMONE METABOLISM; HUMAN; MEDICAL ASSESSMENT; NOMENCLATURE; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW;

ANIMALS; DEHYDROEPIANDROSTERONE; DISEASE MODELS, ANIMAL; ESTROGENS; FEMALE; GONADAL STEROID HORMONES; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; MUSCLE, SMOOTH, VASCULAR; PULMONARY ARTERY; SEX FACTORS; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR REMODELING;

EID: 77749279521     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.09.88     Document Type: Review

References (88)

1. Rabinovitch M: Molecular pathogenesis of pulmonary arterial hypertension. J. Clin. Invest. 118(7), 2372-2379 (2008).
2. Barst RJ, Gibbs JS, Ghofrani HA et al.: Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54(Suppl. 1), S78-S84 (2009).
3. Simonneau G, Robbins IM, Beghetti M et al.: Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54(Suppl. 1), S43-S54 (2009).
4. Humbert M, Sitbon O, Chaouat A et al.: Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 173(9), 1023-1030 (2006).
5. Badesch DB, Champion HC, Sanchez MA et al.: Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54(Suppl. 1), S55-S66 (2009).
6. Fisher MR, Forfia PR, Chamera E et al.: Accuracy of doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am. J. Respir. Crit. Care Med. 179(7), 615-621 (2009).
7. Hemnes AR, Forfia PR, Champion HC: Assessment of pulmonary vasculature and right heart by invasive haemodynamics and echocardiography. Int. J. Clin. Pract. Suppl. 162, 4-19 (2009).
8. Pietra GG, Capron F, Stewart S et al.: Pathologic assessment of vasculopathies in pulmonary hypertension. J. Am. Coll. Cardiol. 43(12 Suppl. S), S25-S32 (2004).
9. Lantuejoul S, Sheppard MN, Corrin B, Burke MM, Nicholson AG: Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am. J. Surg. Pathol. 30(7), 850-857 (2006).
10. Oudiz RJ: Pulmonary hypertension associated with left-sided heart disease. Clin. Chest Med. 28(1), 233-241, X (2007).
11. Moraes DL, Colucci WS, Givertz MM: Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 102(14), 1718-1723 (2000).
12. Packer M, McMurray J, Massie BM et al.: Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J. Card. Fail. 11(1), 12-20 (2005).
13. Califf RM, Adams KF, McKenna WJ et al.: A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am. Heart J. 134(1), 44-54 (1997).
14. Lewis GD, Lachmann J, Camuso J et al.: Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115(1), 59-66 (2007).
15. Lewis GD, Shah R, Shahzad K et al.: Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 116(14), 1555-1562 (2007).
16. Tedford RJ, Hemnes AR, Russell SD et al.: PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ. Heart Fail. 1(4), 213-219 (2008).
17. Takimoto E, Champion HC, Li M et al.: Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. 11(2), 214-222 (2005).
18. Rich S, Dantzker DR, Ayres SM et al.: Primary pulmonary hypertension. A national prospective study. Ann. Intern. Med. 107(2), 216-223 (1987).
19. Yigla M, Kramer MR, Bendayan D, Reisner SA, Solomonov A: Unexplained severe pulmonary hypertension in the elderly: report on 14 patients. Isr. Med. Assoc. J. 6(2), 78-81 (2004).
20. Badesch DB, Raskob GE, Elliot CG et al.: Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest 137(2), 376-387 (2010).
21. Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA 3rd, Newman JH: Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 152(1), 93-97 (1995).
22. Kawut SM, Krowka MJ, Trotter JF et al.: Clinical risk factors for portopulmonary hypertension. Hepatology 48(1), 196-203 (2008).
23. Deng Z, Morse JH, Slager SL et al.: Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet. 67(3), 737-744 (2000).
24. Newman JH, Wheeler L, Lane KB et al.: Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N. Engl. J. Med. 345(5), 319-324 (2001).
25. Aldred MA, Vijayakrishnan J, James V et al.: BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum. Mutat. 27(2), 212-213 (2006).
26. Thomson JR, Machado RD, Pauciulo MW et al.: Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J. Med. Genet. 37(10), 741-745 (2000).
27. Machado RD, Eickelberg O, Elliott CG et al.: Genetics and genomics of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54(Suppl. 1), S32-S42 (2009).
28. Austin ED, Cogan JD, West JD et al.: Alterations in estrogen metabolism: implications for higher penetrance of FPAH in females. Eur. Respir. J. 34(5), 1093-1099 (2009).
29. Elliott CG, Glissmeyer EW, Havlena GT et al.: Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation 113(21), 2509-2515 (2006).
30. Sztrymf B, Coulet F, Girerd B et al.: Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am. J. Respir. Crit. Care Med. 177(12), 1377-1383 (2008).
31. Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S: Pathology of pulmonary hypertension. Clin. Chest Med. 28(1), 23-42, VII (2007).
32. Christman BW, McPherson CD, Newman JH et al.: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327(2), 70-75 (1992).
33. Tuder RM, Cool CD, Geraci MW et al.: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 159(6) 1925-1932 (1999).
34. Giaid A, Saleh D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333(4), 214-221 (1995).
35. Giaid A, Yanagisawa M, Langleben D et al.: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328(24), 1732-1739 (1993).
36. Farber HW, Loscalzo J: Pulmonary arterial hypertension. N. Engl. J. Med. 351(16), 1655-1665 (2004).
37. McLaughlin V V, Archer SL, Badesch DB et al.; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc.; Pulmonary Hypertension Association: ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol. 53(17), 1573-1619 (2009).
38. Sitbon O, Humbert M, Jais X et al.: Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111(23), 3105-3111 (2005).
39. Channick RN, Simonneau G, Sitbon O et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358(9288), 1119-1123 (2001).
40. Galie N, Rubin L, Hoeper M et al.: Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630), 2093-2100 (2008).
41. Rubin LJ, Badesch DB, Barst RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346(12), 896-903 (2002).
42. Galie N, Badesch D, Oudiz R et al.: Ambrisentan therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 46(3), 529-535 (2005).
43. Galie N, Olschewski H, Oudiz RJ et al.: Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117(23) 3010-3019 (2008).
44. Galie N, Ghofrani HA, Torbicki A et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353(20), 2148-2157 (2005).
45. Galie N, Brundage BH, Ghofrani HA et al.: Tadalafil therapy for pulmonary arterial hypertension. Circulation 119(22), 2894-2903 (2009).
46. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M: The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 112(3), 714-721 (1997).
47. Johnson SR, Mehta S, Granton JT: Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur. Respir. J. 28(5), 999-1004 (2006).
48. Rahman A, Isenberg DA: Systemic lupus erythematosus. N. Engl. J. Med. 358(9), 929-939 (2008).
49. Gabrielli A, Avvedimento EV, Krieg T: Scleroderma. N. Engl. J. Med. 360(19), 1989-2003 (2009).
50. Shinomiya F, Mima N, Nanba K et al.: Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period. Mod. Rheumatol. 18(2), 165-169 (2008).
51. Payne AH, Hales DB: Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr. Rev. 25(6), 947-970 (2004).
52. Lahm T, Crisostomo PR, Markel TA et al.: The effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary vasoconstriction: potential new clinical implications for an old hormone. Crit. Care Med. 36(7), 2174-2183 (2008).
53. Tofovic SP, Zhang X, Jackson EK, Zhu H, Petrusevska G: 2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. Vascul. Pharmacol. 51(2-3), 190-197 (2009).
54. Tofovic SP, Zhang X, Zhu H, Jackson EK, Rafikova O, Petrusevska G: 2-ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling. Vascul. Pharmacol. 48(4-6), 174-183 (2008).
55. Zhu BT, Conney AH: Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19(1), 1-27 (1998).
56. Meldrum DR: G-protein-coupled receptor 30 mediates estrogen's nongenomic effects after hemorrhagic shock and trauma. Am. J. Pathol. 170(4), 1148-1151 (2007).
57. West J, Harral J, Deng Y et al.: Mice expressing BMPR2r899x transgene in smooth muscle develop pulmonary vascular lesions. Circ. Res. 295(5), L744-L755 (2007).
58. Lahm T, Patel KM, Crisostomo PR et al.: Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle. Am. J. Physiol. Endocrinol. Metab. 293(3), E865-E871 (2007).
59. Lahm T, Crisostomo PR, Markel TA et al.: Selective estrogen receptor-α and estrogen receptor-β agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide dependent mechanism. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295(5), R1486-R1493 (2008).
60. Moore LG, McMurtry IF, Reeves JT: Effects of sex hormones on cardiovascular and hematologic responses to chronic hypoxia in rats. Proc. Soc. Exp. Biol. Med. 158(4), 658-662 (1978).
61. Rabinovitch M, Gamble WJ, Miettinen OS, Reid L: Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am. J. Physiol. 240(1), H62-H72 (1981).
62. McMurtry IF, Frith CH, Will DH: Cardiopulmonary responses of male and female swine to simulated high altitude. J. Appl. Physiol. 35(4), 459-462 (1973).
63. Tofovic SP, Zhang X, Jackson EK, Dacic S, Petrusevska G: 2-methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul. Pharmacol. 45(6), 358-367 (2006).
64. Resta TC, Kanagy NL, Walker BR: Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. Am. J. Physiol. Lung Cell Mol. Physiol. 280(1), L88-L97 (2001).
65. English KM, Jones RD, Jones TH, Morice AH, Channer KS: Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm. Metab. Res. 33(11), 645-652 (2001).
66. Jones RD, English KM, Pugh PJ, Morice AH, Jones TH, Channer KS: Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action. J. Cardiovasc. Pharmacol. 39(6), 814-823 (2002).
67. Smith AM, Bennett RT, Jones TH, Cowen ME, Channer KS, Jones RD: Characterization of the vasodilatory action of testosterone in the human pulmonary circulation. Vasc. Health Risk Manag. 4(6), 1459-1466 (2008).
68. +-channel opener. Am. J. Physiol. 274(2 Pt 1), L186-L195 (1998).
69. Oka M, Karoor V, Homma N et al.: Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. Cardiovasc. Res. 74(3), 377-387 (2007).
70. Homma N, Nagaoka T, Karoor V et al.: Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone. Am. J. Physiol. Lung Cell Mol. Physiol. 295(1), L71-L78 (2008).
71. West J, Cogan J, Geraci M et al.: Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med. Genomics 1, 45 (2008).
72. Diergaarde B, Potter JD, Jupe ER et al.: Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Cancer Epidemiol. Biomarkers Prev. 17(7), 1751-1759 (2008).
73. Roos PH, Bolt HM: Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1. Expert Opin. Drug Metab. Toxicol. 1(2), 187-202 (2005).
74. Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O: Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer. Cancer Lett. 221(2), 185-190 (2005).
75. Wenzlaff AS, Cote ML, Bock CH et al.: CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 26(12), 2207-2212 (2005).
76. Yager JD, Davidson NE: Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354(3), 270-282 (2006).
77. Spivack SD, Hurteau GJ, Reilly AA, Aldous KM, Ding X, Kaminsky LS: CYP1B1 expression in human lung. Drug Metab. Dispos. 29(6), 916-922 (2001).
78. Kim JH, Sherman ME, Curriero FC, Guengerich FP, Strickland PT, Sutter TR: Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol. Appl. Pharmacol. 199(3), 210-219 (2004).
79. Muti P, Bradlow HL, Micheli A et al.: Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16a-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 11(6), 635-640 (2000).
80. Roberts KE, Fallon MB, Krowka MJ et al.: Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am. J. Respir. Crit. Care Med. 179(9), 835-842 (2009).
81. Beretta L, Caronni M, Origgi L, Ponti A, Santaniello A, Scorza R: Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Scand. J. Rheumatol. 35(6), 468-471 (2006).
82. Morse JH, Horn EM, Barst RJ: Hormone replacement therapy: a possible risk factor in carriers of familial primary pulmonary hypertension. Chest 116(3), 847 (1999).
83. D'Alonzo GE, Barst RJ, Ayres SM et al.: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115(5), 343-349 (1991).
84. Kawut SM, Al-Naamani N, Agerstrand C et al.: Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest 135(3), 752-759 (2009).
85. Tandri H, Daya SK, Nasir K et al.: Normal reference values for the adult right ventricle by magnetic resonance imaging. Am. J. Cardiol. 98(12), 1660-1664 (2006).
86. Weiss BM, Zemp L, Seifert B, Hess OM: Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J. Am. Coll. Cardiol. 31(7), 1650-1657 (1998).
87. Bedard E, Dimopoulos K, Gatzoulis MA: Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur. Heart J. 30(3), 256-265 (2009).
88. Hemnes AR, Robbins IM: Hysteroscopic sterilization in women with pulmonary vascular disease. Mayo Clin. Proc. 83(10), 1188-1189; author reply 1189 (2008).